$14.91
-0.40-2.61%
Last update: Nov 10, 5:17 PM
Trevi Therapeutics Inc
TRVINASDAQ
Trevi Therapeutics rose 26.5% from $12.10 to $15.31, ahead of the S&P 500's +9.8%. Its worst day was Jul 20 (−12.1%), and its low came Jan 23 at $9.99.
Nov 11, 2025 – Nov 9, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
EPS of $-0.08 beat the $-0.10 estimate on $0.00 revenue.
−0.8% · S&P 500 0.0%
Trevi Therapeutics shares rose 17.0%, while the S&P 500 rose 0.7%.
Story events cover the past 12 months · Times ET
+17.0%, the year's best day · S&P 500 +0.7%
Trevi Therapeutics closed at its lowest level of the year, 17.4% below where the year started.
−8.7% · S&P 500 0.0%
Trevi Therapeutics shares fell 12.0%, while the S&P 500 rose 0.9%.
−12.0% · S&P 500 +0.9%
EPS of $-0.06 beat the $-0.10 estimate on $0.00 revenue.
−4.5% · S&P 500 −1.4%
EPS of $-0.09 missed the $-0.07 estimate on $0.00 revenue.
−2.7% · S&P 500 +1.4%
Trevi Therapeutics closed at its highest level of the year, 61.2% above where the year started.
+8.6% · S&P 500 −0.5%
Trevi Therapeutics shares fell 12.1%, while the S&P 500 fell 0.2%.
−12.1%, the year's worst day · S&P 500 −0.2%
EPS of $-0.11 beat the $-0.11 estimate on $0.00 revenue.
+0.1% · S&P 500 +0.6%
Where it ended: a close of $15.31 on Nov 9, 2026.
Nothing in the past 12 months.
All TRVI dividend historyChart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for TRVI and SPY from Benzinga historical bars. Not investment advice.
